PIK3CA and cancer: Crucially, these recent data demonstrate a level of robustness in PI3K signalling, suggesting that pan-Class I PI3K inhibitors or the combination of potent PI3Kα and PI3Kβ inhibitors may ultimately be required to impact different cancers by suppressing or overcoming the upregulation of the non-targeted PI3K isoforms.